Description
What Is Filagra DXT Plus 100+60 mg?
Filagra DXT Plus 100+60 mg is a fixed-dose combination tablet containing sildenafil citrate 100 mg and duloxetine hydrochloride 60 mg for the concurrent management of erectile dysfunction (ED) and premature ejaculation (PE) in adult men. It is the higher-dose variant of Filagra DXT — providing the same sildenafil 100 mg PDE5 inhibitor dose for erectile dysfunction, but with duloxetine 60 mg (double the 30 mg dose in Filagra DXT) for men who require stronger ejaculatory delay, have established that duloxetine 30 mg provides insufficient PE control, or whose PE severity warrants the stronger SNRI dose from the outset.
Duloxetine 60 mg is the standard dose used in clinical trials of duloxetine for premature ejaculation and corresponds to the minimum effective antidepressant dose for duloxetine — suggesting it provides maximum ejaculatory delay effect within a dose range that most men tolerate. The combination of sildenafil 100 mg + duloxetine 60 mg represents a comprehensive, maximal-efficacy single-tablet approach for men presenting with both significant ED and PE, where complete management of both disorders is the therapeutic goal. It is appropriate where the lower-dose Filagra DXT 100+30 mg has been tried and found to provide insufficient PE control, or as the initial treatment choice in men with severe or primary PE.
Mechanism of Action
Sildenafil 100 mg — PDE5 Inhibition and Erection
Sildenafil is a potent, selective inhibitor of phosphodiesterase type 5 (PDE5), the dominant enzyme metabolising cyclic guanosine monophosphate (cGMP) in corpus cavernosum smooth muscle. During sexual stimulation, nitric oxide (NO) release from non-adrenergic, non-cholinergic nerve endings and endothelial cells in the corpus cavernosum activates guanylyl cyclase, generating cGMP. cGMP activates protein kinase G, reduces intracellular calcium in smooth muscle cells, and causes vasodilation and erection. Sildenafil’s inhibition of PDE5 prolongs cGMP accumulation and amplifies the erectile response to stimulation. The 100 mg dose represents maximum licensed PDE5 inhibition for on-demand use.
Duloxetine 60 mg — Serotonin–Norepinephrine Reuptake Inhibition
Duloxetine 60 mg provides potent inhibition of presynaptic serotonin (5-HT) and norepinephrine (NE) transporters, raising intrasynaptic concentrations of both neurotransmitters throughout central and spinal circuits. For ejaculatory control, the critical circuit is the spinal ejaculatory generator — a lumbosacral interneuron network regulated by descending serotonergic pathways from the brainstem nucleus paragigantocellularis. Elevated 5-HT at spinal serotonin receptors (particularly 5-HT₁B and 5-HT₂C) increases inhibitory tone on spinal ejaculatory neurons, raising the threshold of stimulation required to trigger ejaculation and effectively prolonging intravaginal ejaculatory latency time (IELT). The 60 mg dose produces a substantially greater degree of ejaculatory inhibition than the 30 mg dose, reflected in clinically meaningful prolongation of IELT in clinical studies of duloxetine for PE.
On-Demand versus Daily Dosing of Duloxetine
Unlike SSRIs (which typically require daily dosing for sustained synaptic 5-HT elevation and consistent PE control), duloxetine at 60 mg has been studied in both daily and on-demand regimens for PE. On-demand use 1–2 hours before sexual activity produces measurable ejaculatory delay, though daily regimens may produce greater and more consistent IELT prolongation over time by achieving stable synaptic 5-HT elevations. Filagra DXT Plus is designed for on-demand use to align with the on-demand dosing profile of sildenafil.
Indications
Concurrent Erectile Dysfunction and Premature Ejaculation (Higher-Dose PE Requirement)
Filagra DXT Plus 100+60 mg is indicated for adult men with concomitant erectile dysfunction and premature ejaculation who require higher-dose ejaculatory inhibition alongside PDE5-inhibitor therapy for ED. The clinical scenario is typically: (a) men who have tried Filagra DXT 100+30 mg and found duloxetine 30 mg insufficient for PE control; (b) men with severe lifelong PE (IELT consistently <1 minute) for whom the 60 mg dose is selected as the starting regimen; or (c) men in whom PE is the dominant complaint and duloxetine 60 mg is the preferred first-line SNRI dose, combined with sildenafil for concurrent ED management.
Dosage and Administration
Standard dose: One tablet (sildenafil 100 mg + duloxetine 60 mg) taken 1–2 hours before anticipated sexual activity.
Timing: 1–2 hours before activity. The extended lead time compared to sildenafil alone accounts for duloxetine’s slower onset of ejaculatory effect relative to sildenafil’s erectile effect.
Frequency: On-demand; maximum one tablet per 24-hour period.
Food effect: High-fat meals delay sildenafil absorption — take at least 2 hours after a high-fat meal to avoid blunted sildenafil onset. Duloxetine absorption is less affected by food; taking with food may reduce duloxetine-related nausea.
Renal impairment: Avoid in severe renal impairment. Use with caution in moderate impairment.
Hepatic impairment: Avoid in moderate to severe hepatic impairment — both components have significantly increased exposure with hepatic dysfunction.
Elderly: Both sildenafil and duloxetine have increased exposure in elderly patients. Consider whether the standard Filagra DXT 100+30 mg dose is more appropriate for older men before initiating the 60 mg duloxetine dose.
Contraindications
- Organic nitrates (absolute): GTN, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite (“poppers”) — combined severe hypotension with sildenafil.
- MAO inhibitors (absolute): Phenelzine, tranylcypromine, selegiline, linezolid, methylene blue — serotonin syndrome risk with duloxetine component. Allow ≥14 days after stopping a MAOI before initiating duloxetine-containing products, and ≥5 days after stopping duloxetine before starting a MAOI.
- Hypersensitivity to sildenafil, duloxetine, or any excipient.
- Severe cardiovascular disease where sexual activity is contraindicated.
- Severe hepatic or severe renal impairment.
- Uncontrolled narrow-angle glaucoma (duloxetine).
- Riociguat or other soluble guanylate cyclase stimulators (sildenafil — severe hypotension).
Warnings and Precautions
Serotonin syndrome: The duloxetine 60 mg component substantially elevates synaptic serotonin and carries a meaningful serotonin syndrome risk when combined with other serotonergic medications — SSRIs, other SNRIs, triptans, tramadol, fentanyl, lithium, St John’s Wort. This risk is greater with 60 mg than with 30 mg. Carefully review all concurrent medications before prescribing Filagra DXT Plus. Patients should be counselled to report symptoms of serotonin syndrome: agitation, confusion, rapid heart rate, hypertension, dilated pupils, muscle twitching, diarrhoea, fever.
Cardiovascular (sildenafil): The absolute nitrate contraindication applies. Assess cardiovascular fitness for sexual activity. The combined haemodynamic effect of sildenafil (vasodilation, blood pressure reduction) with concurrent antihypertensive therapy, alpha-blockers, or alcohol consumption should be considered.
Nausea at 60 mg duloxetine: Nausea is significantly more common at duloxetine 60 mg than at 30 mg, particularly at initiation. Taking with or immediately after food substantially reduces nausea — advise patients accordingly on first use.
Urinary hesitancy: Duloxetine’s norepinephrine activity strengthens urethral sphincter tone and may cause urinary hesitancy or acute urinary retention, particularly in men with pre-existing lower urinary tract symptoms, benign prostatic hyperplasia, or concurrent alpha-blocker use at insufficient doses.
Blood pressure: Duloxetine can modestly elevate blood pressure through norepinephrine reuptake inhibition. Monitor blood pressure in hypertensive patients, particularly at initiation of duloxetine 60 mg.
Priapism: PDE5 inhibitor-related prolonged erection (>4 hours) requires immediate medical attention.
Adverse Effects
- Sildenafil-related: Headache, flushing, nasal congestion, dyspepsia, visual disturbances (blue-tinged vision, photophobia), dizziness.
- Duloxetine-related (more prominent at 60 mg than 30 mg): Nausea (most common — take with food), dry mouth, fatigue, insomnia, hyperhidrosis, constipation, decreased appetite.
- Additive: Dizziness (combined vasodilatory + CNS effects), tachycardia, hypotension (particularly with concurrent antihypertensives or alpha-blockers).
Drug Interactions
- Nitrates: Absolute contraindication — severe hypotension.
- MAOIs: Absolute contraindication — serotonin syndrome.
- CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, erythromycin): Markedly increase sildenafil exposure — reduce sildenafil-containing combination or avoid.
- CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, enoxacin): Significantly increase duloxetine AUC — contraindicated with fluvoxamine; use with caution with other CYP1A2 inhibitors.
- CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine): Increase duloxetine exposure — monitor for duloxetine adverse effects.
- Other serotonergic agents: Increased serotonin syndrome risk — SSRIs, SNRIs, triptans, tramadol, St John’s Wort, linezolid, methylene blue.
- Alpha-blockers and antihypertensives: Additive hypotension (sildenafil and duloxetine both have vasodilatory/blood pressure effects).
- Anticoagulants (warfarin, NSAIDs, aspirin): Duloxetine may modestly increase bleeding risk through serotonergic platelet effects — monitor INR with warfarin.
Storage
Store below 25°C in a cool, dry place away from direct sunlight and moisture. Keep in the original blister packaging until use. Keep out of reach of children. Do not use after the expiry date printed on the packaging.
Related Products
For the lower duloxetine dose combination (sildenafil 100 mg + duloxetine 30 mg), see Filagra DXT 100+30 mg. For sildenafil 50 mg alone without PE management, see Zenegra 50 mg Tablets. For tadalafil 20 mg + dapoxetine 60 mg combination, see Super Tadalis SX.
References
- National Library of Medicine MedlinePlus. Sildenafil. Available at: https://medlineplus.gov/druginfo/meds/a699015.html
- National Library of Medicine MedlinePlus. Duloxetine. Available at: https://medlineplus.gov/druginfo/meds/a604030.html
- Mayo Clinic. Duloxetine (Oral Route). Available at: https://www.mayoclinic.org
- Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–641. PubMed PMID: 29746562
- Althof SE, McMahon CG, Waldinger MD, et al. An Update of the International Society of Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation (PE). Sex Med. 2014;2(2):60–90. PubMed PMID: 25356297


Reviews
There are no reviews yet.